These are legit concerns investors need to factor in regarding their decision to buy, sell or hold the stock. Personally I think the departures of CMO and CSO carry more weight than the CFO's in OncoSec's case as I think they got a more qualified CFO to replace the old one. Also, my opinion only, departure of key figures in a small company may indicate it could slowly be winding down. Only question is, could they be winding down involuntarily or voluntarily? I'm hoping it's the latter by selling the company :) Nonetheless, valid concerns for a small company when key figures depart.